Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028
Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028
Abstract
The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%.
The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market. However, alternative modes of drug delivery such as oral, nasal, and topical among others are expected to restrain market growth to a certain extent.
The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.
“By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market”
Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market”
Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.
“North America: the largest share of the autoinjectors market”
North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.
“Asia Pacific: The fastest-growing region in the autoinjectors market.”
The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.
The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 70% and Demand Side 30%
•By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
•By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America- 10%, and Middle East & Africa- 5%
Prominent Players
•Becton, Dickinson and Company (BD) (US)
•Ypsomed Holding AG (Switzerland)
•sSHL Medical (Switzerland)
•West Pharmaceutical Services, Inc. (US)
•Recipharm AB (Sweden)
•Haselmeier GmbH (Germany)
•Owen Mumford Ltd. (UK)
•Gerresheimer AG (Germany)
•Phillips-Medisize, LLC (US)
•Oval Medical Technologies Ltd. (UK)
•Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
•Elcam Drug Delivery Devices (E3D) (Israel)
•Crossject (France)
•Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
•Jabil, Inc. (US)
•Congruence Medical Solutions LLC (US)
•AbbVie Inc. (US)
•Amgen Inc. (US)
•Eli Lilly and Company (US)
•Novartis AG (Switzerland)
•Merck KGaA (Germany)
•Viatris Inc. (US)
•Biogen (US)
Research Coverage:
This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers
•Analysis of key drivers (the benefits of autoinjectors in emergency medical care, growth in the number of regulatory approvals, availability of generic versions of autoinjectors, government support and favorable reimbursements, and the growing adoption of self-administration), restraints (alternative drug delivery modes and needle phobia), opportunities (patent expiry of biologics and the increasing shift of therapy to home settings), and challenges (development of autoinjectors for multiple drug viscosities) influencing the growth of the autoinjectors market.
•Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
•Market Development: Comprehensive information about lucrative markets- the report analyses the autoinjectors market across varied regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical among others in the autoinjectors devices market.
Content
Table of Contents
1INTRODUCTION48
1.1STUDY OBJECTIVES48
1.2MARKET DEFINITION48
1.2.1INCLUSIONS AND EXCLUSIONS49
1.3MARKET SCOPE50
FIGURE 1AUTOINJECTORS MARKET SEGMENTATION50
1.3.1YEARS CONSIDERED50
1.4CURRENCY CONSIDERED51
1.5LIMITATIONS51
1.6STAKEHOLDERS51
1.7SUMMARY OF CHANGES52
1.7.1RECESSION IMPACT53
2RESEARCH METHODOLOGY54
2.1RESEARCH DATA54
FIGURE 2RESEARCH DESIGN54
2.1.1SECONDARY DATA55
2.1.2PRIMARY DATA55
FIGURE 3AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES56
2.2MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES57
FIGURE 4MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES57
FIGURE 5AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH57
FIGURE 6MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)58
2.3MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS59
FIGURE 7MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS59
FIGURE 8MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)60
2.3.1INSIGHTS FROM PRIMARIES61
FIGURE 9MARKET VALIDATION FROM PRIMARY EXPERTS61
FIGURE 10MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH62
2.4GROWTH FORECAST63
FIGURE 11AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS63
FIGURE 12AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS64
FIGURE 13AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES64
2.5MARKET BREAKDOWN AND DATA TRIANGULATION65
FIGURE 14DATA TRIANGULATION METHODOLOGY65
2.6RESEARCH ASSUMPTIONS66
2.7RISK ANALYSIS66
2.8IMPACT OF RECESSION ON AUTOINJECTORS MARKET66
TABLE 1GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)66
3EXECUTIVE SUMMARY68
FIGURE 15AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)68
FIGURE 16AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)69
FIGURE 17AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)69
FIGURE 18AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)70
FIGURE 19AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)70
FIGURE 20AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)71
FIGURE 21GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET72
FIGURE 22GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET72
4PREMIUM INSIGHTS74
4.1AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW74
FIGURE 23INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH74
4.2NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022)75
FIGURE 24DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 202275
4.3NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)75
FIGURE 25SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 202275
4.4AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)76
FIGURE 26RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 202876
4.5OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 202276
FIGURE 27MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 202276
4.6AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES77
FIGURE 28ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 202877
4.7AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES78
FIGURE 29ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 202878
5MARKET OVERVIEW79
5.1INTRODUCTION79
5.2MARKET DYNAMICS79
FIGURE 30AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES79
TABLE 2AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES80
5.2.1DRIVERS80
5.2.1.1Benefits of autoinjectors in emergency medical care80
5.2.1.2Increasing regulatory approvals for autoinjectors81
TABLE 3RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE81
5.2.1.3Availability of generics and biosimilars in autoinjectors82
5.2.1.4Government support and favorable reimbursements82
5.2.1.5Growing awareness and adoption of self-administration82
5.2.2RESTRAINTS83
5.2.2.1Alternative drug delivery modes and needle phobia83
5.2.3OPPORTUNITIES83
5.2.3.1Patent expiry of biologics83
TABLE 4PATENT EXPIRY OF KEY BIOLOGICS84
5.2.3.2Increasing shift of therapy to home settings84
5.2.4CHALLENGES85
5.2.4.1Development of autoinjectors for multiple drug viscosities85
5.3KEY INDUSTRY TRENDS85
5.3.1INCREASING ADOPTION OF WEARABLE AUTOINJECTORS85
5.3.2DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS86
5.4TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES86
FIGURE 31REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS86
5.5PRICING ANALYSIS87
TABLE 5AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 202087
TABLE 6INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS87
5.6VALUE CHAIN ANALYSIS88
FIGURE 32AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS88
5.7SUPPLY CHAIN ANALYSIS90
FIGURE 33AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS90
TABLE 7OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS91
5.8ECOSYSTEM ANALYSIS92
FIGURE 34ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET92
5.9TECHNOLOGY ANALYSIS92
5.10PATENT ANALYSIS93
FIGURE 35PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 202393
TABLE 8INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET94
5.11KEY CONFERENCES AND EVENTS IN 2023–202495
TABLE 9AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS95
5.12TRADE DATA96
TABLE 10IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 202296
5.13REGULATORY ANALYSIS97
5.13.1REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 11NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 12EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 13ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS99
TABLE 14REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS100
5.14PORTER’S FIVE FORCES ANALYSIS101
TABLE 15AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS101
5.14.1THREAT OF NEW ENTRANTS101
5.14.2THREAT OF SUBSTITUTES101
5.14.3BARGAINING POWER OF SUPPLIERS101
5.14.4BARGAINING POWER OF BUYERS101
5.14.5INTENSITY OF COMPETITIVE RIVALRY101
5.15KEY STAKEHOLDERS AND BUYING CRITERIA102
5.15.1KEY STAKEHOLDERS IN BUYING PROCESS102
FIGURE 36INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES102
5.15.2BUYING CRITERIA FOR AUTOINJECTOR DEVICES102
FIGURE 37KEY BUYING CRITERIA FOR END USERS102
6AUTOINJECTORS MARKET, BY USAGE103
6.1INTRODUCTION104
TABLE 16AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)104
TABLE 17AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (MILLION UNITS)104
TABLE 18AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)104
6.2DISPOSABLE AUTOINJECTORS105
6.2.1CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH105
TABLE 19DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)105
TABLE 20DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)105
TABLE 21NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 22EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 23ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 24DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)107
TABLE 25NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)107
TABLE 26EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)108
TABLE 27ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)108
6.3REUSABLE AUTOINJECTORS108
6.3.1REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET108
TABLE 28REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)109
TABLE 29REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)109
TABLE 30NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)109
TABLE 31EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)110
TABLE 32ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)110
TABLE 33REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)111
TABLE 34NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)111
TABLE 35EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)111
TABLE 36ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)112
7AUTOINJECTORS MARKET, BY TECHNOLOGY113
7.1INTRODUCTION114
TABLE 37AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)114
TABLE 38AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS)114
TABLE 39AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)114
7.2MANUAL AUTOINJECTORS115
7.2.1MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD115
TABLE 40MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)115
TABLE 41MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)116
TABLE 42NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)116
TABLE 43EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)116
TABLE 44ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)117
TABLE 45MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)117
TABLE 46NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)117
TABLE 47EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)118
TABLE 48ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)118
7.3AUTOMATIC AUTOINJECTORS118
7.3.1AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS118
TABLE 49AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)119
TABLE 50AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)120
TABLE 51NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)120
TABLE 52EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)120
TABLE 53ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)121
TABLE 54AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)121
TABLE 55NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)121
TABLE 56EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)122
TABLE 57ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)122
8AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION123
8.1INTRODUCTION124
TABLE 58AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)124
TABLE 59AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (MILLION UNITS)124
8.2SUBCUTANEOUS124
8.2.1INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH124
TABLE 60AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)125
TABLE 61SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)125
TABLE 62NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
TABLE 63EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
TABLE 64ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
8.3INTRAMUSCULAR127
8.3.1INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION127
TABLE 65AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)127
TABLE 66INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)128
TABLE 67NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)128
TABLE 68EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)128
TABLE 69ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)129
9AUTOINJECTORS MARKET, BY THERAPY AREA130
9.1INTRODUCTION131
TABLE 70AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)131
TABLE 71AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS)131
TABLE 72AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)132
9.2RHEUMATOID ARTHRITIS132
9.2.1BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH132
TABLE 73AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)133
TABLE 74AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (MILLION UNITS)133
TABLE 75NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)133
TABLE 76EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)134
TABLE 77ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)134
TABLE 78AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)135
TABLE 79NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)135
TABLE 80EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)135
TABLE 81ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)136
9.3DIABETES136
9.3.1LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS136
FIGURE 38DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS), 2019 VS. 2030 VS. 2045137
TABLE 82AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)137
TABLE 83AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (MILLION UNITS)138
TABLE 84NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)138
TABLE 85EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)138
TABLE 86ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)139
TABLE 87AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)139
TABLE 88NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)139
TABLE 89EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)140
TABLE 90ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)140
9.4MULTIPLE SCLEROSIS140
9.4.1AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH140
TABLE 91AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)141
TABLE 92AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (MILLION UNITS)141
TABLE 93NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)141
TABLE 94EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)142
TABLE 95ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)142
TABLE 96AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)143
TABLE 97NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)143
TABLE 98EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)143
TABLE 99ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)144
9.4.2ANAPHYLAXIS144
9.4.2.1Increasing prevalence of food allergies to drive growth144
TABLE 100AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)145
TABLE 101AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (MILLION UNITS)145
TABLE 102NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)145
TABLE 103EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)146
TABLE 104ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)146
TABLE 105AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)147
TABLE 106NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)147
TABLE 107EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)147
TABLE 108ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)148
9.4.3OTHER THERAPY AREAS148
TABLE 109AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)149
TABLE 110AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (MILLION UNITS)149
TABLE 111NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)149
TABLE 112EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)150
TABLE 113ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)150
TABLE 114AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)151
TABLE 115NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)151
TABLE 116EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)151
TABLE 117ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)152
10AUTOINJECTORS MARKET, BY VOLUME153
10.1INTRODUCTION154
TABLE 118AUTOINJECTORS MARKET, BY VOLUME, 2021–2028 (USD MILLION)154
TABLE 119AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (MILLION UNITS)154
10.2UP TO 3 ML VOLUME154
10.2.1INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH154
TABLE 120UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)155
TABLE 121UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)155
10.3ABOVE 3 ML VOLUME (LARGE VOLUME)156
10.3.1GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH156
TABLE 122ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)156
TABLE 123ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)156
11AUTOINJECTORS MARKET, BY END USER157
11.1INTRODUCTION158
TABLE 124AUTOINJECTORS MARKET, BY END USER, 2021–2028 (USD MILLION)158
11.2HOME CARE SETTINGS158
11.2.1COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH158
TABLE 125AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)159
TABLE 126NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)159
TABLE 127EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)160
TABLE 128ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)160
11.3HOSPITALS AND CLINICS161
11.3.1USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH161
TABLE 129AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)161
TABLE 130NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
TABLE 131EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
TABLE 132ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
11.4AMBULATORY CARE SETTINGS163
11.4.1INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH163
TABLE 133AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)163
TABLE 134NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
TABLE 135EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
TABLE 136ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
12AUTOINJECTORS MARKET, BY REGION165
12.1INTRODUCTION166
TABLE 137AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)166
TABLE 138AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)166
12.2NORTH AMERICA167
FIGURE 39NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT167
TABLE 139NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)168
TABLE 140NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)168
TABLE 141NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)168
TABLE 142NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)169
TABLE 143NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)169
TABLE 144NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)169
TABLE 145NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)170
TABLE 146NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)170
TABLE 147NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)170
TABLE 148NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)171
TABLE 149NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)171
TABLE 150NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)171
TABLE 151NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)172
TABLE 152NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)172
12.2.1US172
12.2.1.1US to dominate North American market during forecast period172
TABLE 153AUTOINJECTORS APPROVED BY US FDA, 2022174
TABLE 154US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)174
TABLE 155US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)174
TABLE 156US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)175
TABLE 157US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)175
TABLE 158US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)175
TABLE 159US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)176
TABLE 160US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)176
TABLE 161US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)176
TABLE 162US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)177
TABLE 163US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)177
12.2.2CANADA177
12.2.2.1Rising prevalence of chronic diseases to drive growth177
TABLE 164CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)178
TABLE 165CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)178
TABLE 166CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)178
TABLE 167CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)179
TABLE 168CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)179
TABLE 169CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)179
TABLE 170CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)180
TABLE 171CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)180
TABLE 172CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)180
TABLE 173CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)181
12.2.3NORTH AMERICA: RECESSION IMPACT181
12.3EUROPE182
TABLE 174EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)182
TABLE 175EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)182
TABLE 176EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)182
TABLE 177EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)183
TABLE 178EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)183
TABLE 179EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)183
TABLE 180EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)184
TABLE 181EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)184
TABLE 182EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)184
TABLE 183EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)185
TABLE 184EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)185
TABLE 185EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)185
TABLE 186EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)186
TABLE 187EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)186
12.3.1GERMANY186
12.3.1.1Growing government support to propel market186
TABLE 188GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)187
TABLE 189GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)187
TABLE 190GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)187
TABLE 191GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)188
TABLE 192GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)188
TABLE 193GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)188
TABLE 194GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)189
TABLE 195GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)189
TABLE 196GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)189
TABLE 197GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)190
12.3.2UK190
12.3.2.1High prevalence of allergic conditions to boost growth190
TABLE 198UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)190
TABLE 199UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)191
TABLE 200UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)191
TABLE 201UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)191
TABLE 202UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)192
TABLE 203UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)192
TABLE 204UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)192
TABLE 205UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)193
TABLE 206UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)193
TABLE 207UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)193
12.3.3FRANCE194
12.3.3.1Increasing prevalence of chronic diseases to support growth194
TABLE 208FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)194
TABLE 209FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)194
TABLE 210FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)194
TABLE 211FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)195
TABLE 212FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)195
TABLE 213FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)195
TABLE 214FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)196
TABLE 215FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)196
TABLE 216FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)196
TABLE 217FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)197
12.3.4ITALY197
12.3.4.1Rising prevalence of chronic diseases to propel growth197
TABLE 218ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)197
TABLE 219ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)198
TABLE 220ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)198
TABLE 221ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)198
TABLE 222ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)199
TABLE 223ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)199
TABLE 224ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)199
TABLE 225ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)200
TABLE 226ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)200
TABLE 227ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)200
12.3.5SPAIN201
12.3.5.1Favorable reimbursement scenario to support growth201
TABLE 228SPAIN:
The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market. However, alternative modes of drug delivery such as oral, nasal, and topical among others are expected to restrain market growth to a certain extent.
The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.
“By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market”
Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market”
Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.
“North America: the largest share of the autoinjectors market”
North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.
“Asia Pacific: The fastest-growing region in the autoinjectors market.”
The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.
The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 70% and Demand Side 30%
•By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
•By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America- 10%, and Middle East & Africa- 5%
Prominent Players
•Becton, Dickinson and Company (BD) (US)
•Ypsomed Holding AG (Switzerland)
•sSHL Medical (Switzerland)
•West Pharmaceutical Services, Inc. (US)
•Recipharm AB (Sweden)
•Haselmeier GmbH (Germany)
•Owen Mumford Ltd. (UK)
•Gerresheimer AG (Germany)
•Phillips-Medisize, LLC (US)
•Oval Medical Technologies Ltd. (UK)
•Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
•Elcam Drug Delivery Devices (E3D) (Israel)
•Crossject (France)
•Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
•Jabil, Inc. (US)
•Congruence Medical Solutions LLC (US)
•AbbVie Inc. (US)
•Amgen Inc. (US)
•Eli Lilly and Company (US)
•Novartis AG (Switzerland)
•Merck KGaA (Germany)
•Viatris Inc. (US)
•Biogen (US)
Research Coverage:
This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers
•Analysis of key drivers (the benefits of autoinjectors in emergency medical care, growth in the number of regulatory approvals, availability of generic versions of autoinjectors, government support and favorable reimbursements, and the growing adoption of self-administration), restraints (alternative drug delivery modes and needle phobia), opportunities (patent expiry of biologics and the increasing shift of therapy to home settings), and challenges (development of autoinjectors for multiple drug viscosities) influencing the growth of the autoinjectors market.
•Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
•Market Development: Comprehensive information about lucrative markets- the report analyses the autoinjectors market across varied regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical among others in the autoinjectors devices market.
1INTRODUCTION48
1.1STUDY OBJECTIVES48
1.2MARKET DEFINITION48
1.2.1INCLUSIONS AND EXCLUSIONS49
1.3MARKET SCOPE50
FIGURE 1AUTOINJECTORS MARKET SEGMENTATION50
1.3.1YEARS CONSIDERED50
1.4CURRENCY CONSIDERED51
1.5LIMITATIONS51
1.6STAKEHOLDERS51
1.7SUMMARY OF CHANGES52
1.7.1RECESSION IMPACT53
2RESEARCH METHODOLOGY54
2.1RESEARCH DATA54
FIGURE 2RESEARCH DESIGN54
2.1.1SECONDARY DATA55
2.1.2PRIMARY DATA55
FIGURE 3AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES56
2.2MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES57
FIGURE 4MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES57
FIGURE 5AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH57
FIGURE 6MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)58
2.3MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS59
FIGURE 7MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS59
FIGURE 8MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)60
2.3.1INSIGHTS FROM PRIMARIES61
FIGURE 9MARKET VALIDATION FROM PRIMARY EXPERTS61
FIGURE 10MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH62
2.4GROWTH FORECAST63
FIGURE 11AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS63
FIGURE 12AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS64
FIGURE 13AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES64
2.5MARKET BREAKDOWN AND DATA TRIANGULATION65
FIGURE 14DATA TRIANGULATION METHODOLOGY65
2.6RESEARCH ASSUMPTIONS66
2.7RISK ANALYSIS66
2.8IMPACT OF RECESSION ON AUTOINJECTORS MARKET66
TABLE 1GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)66
3EXECUTIVE SUMMARY68
FIGURE 15AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)68
FIGURE 16AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)69
FIGURE 17AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)69
FIGURE 18AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)70
FIGURE 19AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)70
FIGURE 20AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)71
FIGURE 21GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET72
FIGURE 22GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET72
4PREMIUM INSIGHTS74
4.1AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW74
FIGURE 23INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH74
4.2NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022)75
FIGURE 24DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 202275
4.3NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)75
FIGURE 25SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 202275
4.4AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)76
FIGURE 26RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 202876
4.5OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 202276
FIGURE 27MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 202276
4.6AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES77
FIGURE 28ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 202877
4.7AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES78
FIGURE 29ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 202878
5MARKET OVERVIEW79
5.1INTRODUCTION79
5.2MARKET DYNAMICS79
FIGURE 30AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES79
TABLE 2AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES80
5.2.1DRIVERS80
5.2.1.1Benefits of autoinjectors in emergency medical care80
5.2.1.2Increasing regulatory approvals for autoinjectors81
TABLE 3RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE81
5.2.1.3Availability of generics and biosimilars in autoinjectors82
5.2.1.4Government support and favorable reimbursements82
5.2.1.5Growing awareness and adoption of self-administration82
5.2.2RESTRAINTS83
5.2.2.1Alternative drug delivery modes and needle phobia83
5.2.3OPPORTUNITIES83
5.2.3.1Patent expiry of biologics83
TABLE 4PATENT EXPIRY OF KEY BIOLOGICS84
5.2.3.2Increasing shift of therapy to home settings84
5.2.4CHALLENGES85
5.2.4.1Development of autoinjectors for multiple drug viscosities85
5.3KEY INDUSTRY TRENDS85
5.3.1INCREASING ADOPTION OF WEARABLE AUTOINJECTORS85
5.3.2DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS86
5.4TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES86
FIGURE 31REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS86
5.5PRICING ANALYSIS87
TABLE 5AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 202087
TABLE 6INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS87
5.6VALUE CHAIN ANALYSIS88
FIGURE 32AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS88
5.7SUPPLY CHAIN ANALYSIS90
FIGURE 33AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS90
TABLE 7OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS91
5.8ECOSYSTEM ANALYSIS92
FIGURE 34ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET92
5.9TECHNOLOGY ANALYSIS92
5.10PATENT ANALYSIS93
FIGURE 35PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 202393
TABLE 8INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET94
5.11KEY CONFERENCES AND EVENTS IN 2023–202495
TABLE 9AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS95
5.12TRADE DATA96
TABLE 10IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 202296
5.13REGULATORY ANALYSIS97
5.13.1REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 11NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 12EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98
TABLE 13ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS99
TABLE 14REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS100
5.14PORTER’S FIVE FORCES ANALYSIS101
TABLE 15AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS101
5.14.1THREAT OF NEW ENTRANTS101
5.14.2THREAT OF SUBSTITUTES101
5.14.3BARGAINING POWER OF SUPPLIERS101
5.14.4BARGAINING POWER OF BUYERS101
5.14.5INTENSITY OF COMPETITIVE RIVALRY101
5.15KEY STAKEHOLDERS AND BUYING CRITERIA102
5.15.1KEY STAKEHOLDERS IN BUYING PROCESS102
FIGURE 36INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES102
5.15.2BUYING CRITERIA FOR AUTOINJECTOR DEVICES102
FIGURE 37KEY BUYING CRITERIA FOR END USERS102
6AUTOINJECTORS MARKET, BY USAGE103
6.1INTRODUCTION104
TABLE 16AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)104
TABLE 17AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (MILLION UNITS)104
TABLE 18AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)104
6.2DISPOSABLE AUTOINJECTORS105
6.2.1CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH105
TABLE 19DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)105
TABLE 20DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)105
TABLE 21NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 22EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 23ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)106
TABLE 24DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)107
TABLE 25NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)107
TABLE 26EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)108
TABLE 27ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)108
6.3REUSABLE AUTOINJECTORS108
6.3.1REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET108
TABLE 28REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)109
TABLE 29REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)109
TABLE 30NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)109
TABLE 31EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)110
TABLE 32ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)110
TABLE 33REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)111
TABLE 34NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)111
TABLE 35EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)111
TABLE 36ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)112
7AUTOINJECTORS MARKET, BY TECHNOLOGY113
7.1INTRODUCTION114
TABLE 37AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)114
TABLE 38AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS)114
TABLE 39AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)114
7.2MANUAL AUTOINJECTORS115
7.2.1MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD115
TABLE 40MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)115
TABLE 41MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)116
TABLE 42NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)116
TABLE 43EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)116
TABLE 44ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)117
TABLE 45MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)117
TABLE 46NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)117
TABLE 47EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)118
TABLE 48ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)118
7.3AUTOMATIC AUTOINJECTORS118
7.3.1AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS118
TABLE 49AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)119
TABLE 50AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)120
TABLE 51NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)120
TABLE 52EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)120
TABLE 53ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)121
TABLE 54AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)121
TABLE 55NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)121
TABLE 56EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)122
TABLE 57ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)122
8AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION123
8.1INTRODUCTION124
TABLE 58AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)124
TABLE 59AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (MILLION UNITS)124
8.2SUBCUTANEOUS124
8.2.1INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH124
TABLE 60AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)125
TABLE 61SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)125
TABLE 62NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
TABLE 63EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
TABLE 64ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)126
8.3INTRAMUSCULAR127
8.3.1INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION127
TABLE 65AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)127
TABLE 66INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)128
TABLE 67NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)128
TABLE 68EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)128
TABLE 69ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)129
9AUTOINJECTORS MARKET, BY THERAPY AREA130
9.1INTRODUCTION131
TABLE 70AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)131
TABLE 71AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS)131
TABLE 72AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)132
9.2RHEUMATOID ARTHRITIS132
9.2.1BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH132
TABLE 73AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)133
TABLE 74AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (MILLION UNITS)133
TABLE 75NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)133
TABLE 76EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)134
TABLE 77ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)134
TABLE 78AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)135
TABLE 79NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)135
TABLE 80EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)135
TABLE 81ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)136
9.3DIABETES136
9.3.1LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS136
FIGURE 38DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS), 2019 VS. 2030 VS. 2045137
TABLE 82AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)137
TABLE 83AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (MILLION UNITS)138
TABLE 84NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)138
TABLE 85EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)138
TABLE 86ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)139
TABLE 87AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)139
TABLE 88NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)139
TABLE 89EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)140
TABLE 90ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)140
9.4MULTIPLE SCLEROSIS140
9.4.1AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH140
TABLE 91AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)141
TABLE 92AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (MILLION UNITS)141
TABLE 93NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)141
TABLE 94EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)142
TABLE 95ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)142
TABLE 96AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)143
TABLE 97NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)143
TABLE 98EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)143
TABLE 99ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)144
9.4.2ANAPHYLAXIS144
9.4.2.1Increasing prevalence of food allergies to drive growth144
TABLE 100AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)145
TABLE 101AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (MILLION UNITS)145
TABLE 102NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)145
TABLE 103EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)146
TABLE 104ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)146
TABLE 105AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)147
TABLE 106NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)147
TABLE 107EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)147
TABLE 108ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)148
9.4.3OTHER THERAPY AREAS148
TABLE 109AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)149
TABLE 110AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (MILLION UNITS)149
TABLE 111NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)149
TABLE 112EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)150
TABLE 113ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)150
TABLE 114AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)151
TABLE 115NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)151
TABLE 116EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)151
TABLE 117ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)152
10AUTOINJECTORS MARKET, BY VOLUME153
10.1INTRODUCTION154
TABLE 118AUTOINJECTORS MARKET, BY VOLUME, 2021–2028 (USD MILLION)154
TABLE 119AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (MILLION UNITS)154
10.2UP TO 3 ML VOLUME154
10.2.1INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH154
TABLE 120UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)155
TABLE 121UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)155
10.3ABOVE 3 ML VOLUME (LARGE VOLUME)156
10.3.1GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH156
TABLE 122ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)156
TABLE 123ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)156
11AUTOINJECTORS MARKET, BY END USER157
11.1INTRODUCTION158
TABLE 124AUTOINJECTORS MARKET, BY END USER, 2021–2028 (USD MILLION)158
11.2HOME CARE SETTINGS158
11.2.1COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH158
TABLE 125AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)159
TABLE 126NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)159
TABLE 127EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)160
TABLE 128ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)160
11.3HOSPITALS AND CLINICS161
11.3.1USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH161
TABLE 129AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)161
TABLE 130NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
TABLE 131EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
TABLE 132ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)162
11.4AMBULATORY CARE SETTINGS163
11.4.1INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH163
TABLE 133AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)163
TABLE 134NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
TABLE 135EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
TABLE 136ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)164
12AUTOINJECTORS MARKET, BY REGION165
12.1INTRODUCTION166
TABLE 137AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)166
TABLE 138AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)166
12.2NORTH AMERICA167
FIGURE 39NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT167
TABLE 139NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)168
TABLE 140NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)168
TABLE 141NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)168
TABLE 142NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)169
TABLE 143NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)169
TABLE 144NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)169
TABLE 145NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)170
TABLE 146NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)170
TABLE 147NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)170
TABLE 148NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)171
TABLE 149NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)171
TABLE 150NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)171
TABLE 151NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)172
TABLE 152NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)172
12.2.1US172
12.2.1.1US to dominate North American market during forecast period172
TABLE 153AUTOINJECTORS APPROVED BY US FDA, 2022174
TABLE 154US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)174
TABLE 155US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)174
TABLE 156US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)175
TABLE 157US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)175
TABLE 158US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)175
TABLE 159US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)176
TABLE 160US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)176
TABLE 161US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)176
TABLE 162US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)177
TABLE 163US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)177
12.2.2CANADA177
12.2.2.1Rising prevalence of chronic diseases to drive growth177
TABLE 164CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)178
TABLE 165CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)178
TABLE 166CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)178
TABLE 167CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)179
TABLE 168CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)179
TABLE 169CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)179
TABLE 170CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)180
TABLE 171CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)180
TABLE 172CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)180
TABLE 173CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)181
12.2.3NORTH AMERICA: RECESSION IMPACT181
12.3EUROPE182
TABLE 174EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)182
TABLE 175EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)182
TABLE 176EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)182
TABLE 177EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)183
TABLE 178EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)183
TABLE 179EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)183
TABLE 180EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)184
TABLE 181EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)184
TABLE 182EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)184
TABLE 183EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)185
TABLE 184EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)185
TABLE 185EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)185
TABLE 186EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)186
TABLE 187EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)186
12.3.1GERMANY186
12.3.1.1Growing government support to propel market186
TABLE 188GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)187
TABLE 189GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)187
TABLE 190GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)187
TABLE 191GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)188
TABLE 192GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)188
TABLE 193GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)188
TABLE 194GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)189
TABLE 195GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)189
TABLE 196GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)189
TABLE 197GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)190
12.3.2UK190
12.3.2.1High prevalence of allergic conditions to boost growth190
TABLE 198UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)190
TABLE 199UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)191
TABLE 200UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)191
TABLE 201UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)191
TABLE 202UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)192
TABLE 203UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)192
TABLE 204UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)192
TABLE 205UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)193
TABLE 206UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)193
TABLE 207UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)193
12.3.3FRANCE194
12.3.3.1Increasing prevalence of chronic diseases to support growth194
TABLE 208FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)194
TABLE 209FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)194
TABLE 210FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)194
TABLE 211FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)195
TABLE 212FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)195
TABLE 213FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)195
TABLE 214FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)196
TABLE 215FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)196
TABLE 216FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)196
TABLE 217FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)197
12.3.4ITALY197
12.3.4.1Rising prevalence of chronic diseases to propel growth197
TABLE 218ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)197
TABLE 219ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)198
TABLE 220ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)198
TABLE 221ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)198
TABLE 222ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)199
TABLE 223ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)199
TABLE 224ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)199
TABLE 225ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)200
TABLE 226ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)200
TABLE 227ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)200
12.3.5SPAIN201
12.3.5.1Favorable reimbursement scenario to support growth201
TABLE 228SPAIN:
Related Report
